Brind.
  1. Addex Therapeutics and Indivior are partnering on a drug candidate.

Addex Therapeutics Regains Global Rights to GABAB PAM Assets from Indivior

2 reports, 1 independent Updated Mon 00:00
No new developments lately
Reports
2
Developments
2
Repetition
0%

New informationRepeats or wire copies

AI-generated briefing. Brind wrote this from the reports listed below and has updated it as the story developed. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Addex Therapeutics reported regaining all global rights to the GABAB PAM program from Indivior. This occurred following R&D rationalization at Indivior after its merger with Supernus Pharmaceuticals. The regaining of these rights is noted as solidifying Addex Therapeutics' portfolio of drug candidates targeting GABAB receptor biology.

From manilatimes.net

Why it matters

Some supportBrind's analysis of the reports

The asset regaining provides a valuable addition to Addex Therapeutics' pipeline. This move strengthens the company's core portfolio of novel small molecule allosteric modulators for neurological disorders.

Addex Therapeutics and Indivior are currently partnering on the development of a GABAB PAM drug candidate.

From manilatimes.net

Who's involved

  • IndiviorSpecialty pharmaceuticals business that underwent R&D rationalization.
  • Addex TherapeuticsClinical-stage biopharmaceutical company that regained the GABAB PAM rights.

Who could feel it

Possible knock-on effects

These are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.

  • Addex TherapeuticsSpeculative

    Regaining the GABAB PAM rights could strengthen its competitive position and potentially increase future investment.

  • IndiviorSpeculative

    The R&D rationalization might affect its segment of the business by shifting focus and altering research and development costs.

How it developed

Newest first. Tap a step to see who reported it.
  1. Indivior gave up GABAB PAM rights to Addex Therapeutics.1 source
  2. Indivior and Addex Therapeutics regained full global rights to GABAB PAM assets.1 source

Keep exploring

Part of

Addex Therapeutics and Indivior are partnering on a drug candidate. All 1 developments

The entities involved

Coverage

Newest first; wire copies grouped